1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A novel diagnostic model for insulinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim is to describe a simple and feasible model for the diagnosis of insulinoma. This retrospective study enrolled 37 patients with insulinoma and 44 patients with hypoglycemia not due to insulinoma at the First Affiliated Hospital of Guangxi Medical University. General demographic and clinical characteristics; hemoglobin A1c (HbA1c), insulin and C-peptide concentrations; and the results of 2-h oral glucose tolerance tests (OGTT) were recorded, and a logistic regression model predictive of insulinoma was determined. Body mass index (BMI), HbA1c concentration, 0-h C-peptide concentration, and 0-h and 1-h plasma glucose concentrations ( P  < 0.05 each) were independently associated with insulinoma. A regression prediction model was established through multivariate logistics regression analysis: Logit p = 7.399+(0.310 × BMI) − (1.851 × HbA1c) − (1.467 × 0-h plasma glucose) + (1.963 × 0-h C-peptide) − (0.612 × 1-h plasma glucose). Using this index to draw a receiver operating characteristic (ROC) curve, the area under the curve (AUC) was found to be 0.957. The optimal cut-off value was − 0.17, which had a sensitivity of 89.2% and a specificity of 86.4%. Logit P ≥ − 0.17 can be used as a diagnostic marker for predicting insulinoma in patients with hypoglycemia.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

          Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators despite their relative rarity. Their clinical presentation varies depending on whether the tumor is functional or not, and also according to the specific hormonal syndrome produced. Tumors may be sporadic or inherited, but little is known about their molecular pathology, especially the sporadic forms. Chromogranin A appears to be the most useful serum marker for diagnosis, staging, and monitoring. Initially, therapy should be directed at the hormonal syndrome because this has the major initial impact on the patient's health. Most PETs are relatively indolent but ultimately malignant, except for insulinomas, which predominantly are benign. Surgery is the only modality that offers the possibility of cure, although it generally is noncurative in patients with Zollinger-Ellison syndrome or nonfunctional PETs with multiple endocrine neoplasia-type 1. Preoperative staging of disease extent is necessary to determine the likelihood of complete resection although debulking surgery often is believed to be useful in patients with unresectable tumors. Once metastatic, biotherapy is usually the first modality used because it generally is well tolerated. Systemic or regional therapies generally are reserved until symptoms occur or tumor growth is rapid. Recently, a number of newer agents, as well as receptor-directed radiotherapy, are being evaluated for patients with advanced disease. This review addresses a number of recent advances regarding the molecular pathology, diagnosis, localization, and management of PETs including discussion of peptide-receptor radionuclide therapy and other novel antitumor approaches. We conclude with a discussion of future directions and unsettled problems in the field.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007.

            The objective of the study was to assess changes in the presentation and diagnostic and radiological evaluation of patients with surgically confirmed insulinoma at the Mayo Clinic 1987-2007. A retrospective analysis of patients with insulinoma was conducted. Patients with prior gastric bypass were excluded. A total of 237 patients [135 women (57%)] were identified. Hypoglycemia was reported solely in the fasting state in 73%, the fasting and postprandial state in 21%, and exclusively postprandially in 6%. There was a predominance of men in the postprandial symptom group. Considering the period of study by quartile, outpatient evaluation increased from 35 to 83% and successful preoperative localization improved from 74 to 100% comparing the first to the fourth quartiles. Although the rates of localization by noninvasive techniques remained static at approximately 75%, the addition of invasive modalities has resulted in successful preoperative localization in all patients in the past 10 yr. The sensitivity and specificity of the established diagnostic criteria using insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and glucose response to iv glucagon were greater than 90% and greater than 70%, respectively. Although fasting hypoglycemia is characteristic of patients with insulinoma, postprandial symptoms have been reported with increasing, albeit low, frequency. Trends in the evaluation and preoperative management include a shift to outpatient diagnostic testing, an emphasis on successful preoperative localization to avoid blind pancreatic exploration, and a validation of the diagnostic criteria for hyperinsulinemic hypoglycemia.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma

                Bookmark

                Author and article information

                Contributors
                gxjianghx@163.com
                qinshanyu@gxmu.edu.cn
                Journal
                Discov Oncol
                Discov Oncol
                Discover. Oncology
                Springer US (New York )
                2730-6011
                2 August 2022
                2 August 2022
                December 2022
                : 13
                : 68
                Affiliations
                GRID grid.412594.f, ISNI 0000 0004 1757 2961, Department of Gastroenterology, , The First Affiliated Hospital of Guangxi Medical University, ; No. 6 Shuangyong Road, Nanning, 530021 Guangxi Zhuang Autonomous Region People’s Republic of China
                Article
                534
                10.1007/s12672-022-00534-w
                9346017
                35916979
                10d4179d-ad84-4d2e-b8b5-15eceb38577f
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 May 2022
                : 27 July 2022
                Funding
                Funded by: Guangxi Medical High-level Key Talents “139” Training Program
                Award ID: G201903004
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81960439
                Funded by: Special Fund for Characteristic Innovation Team of Guangxi Natural Science Foundation
                Award ID: YYZS2020007
                Funded by: Technology development and promotion
                Award ID: S2017024
                Categories
                Clinical Trial
                Custom metadata
                © The Author(s) 2022

                insulinoma,hypoglycemia,diagnostic predictive model
                insulinoma, hypoglycemia, diagnostic predictive model

                Comments

                Comment on this article